NRx Pharmaceuticals (NRXP) Set to Announce Quarterly Earnings on Thursday

NRx Pharmaceuticals (NASDAQ:NRXP) will issue its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.81) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.06. On average, analysts expect NRx Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock opened at $1.30 on Friday. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $7.33. The stock has a market cap of $13.98 million, a price-to-earnings ratio of -0.48 and a beta of 1.27. The firm has a fifty day moving average of $1.50 and a 200-day moving average of $2.29.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Ascendiant Capital Markets increased their target price on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. HC Wainwright increased their target price on shares of NRx Pharmaceuticals from $2.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Finally, EF Hutton Acquisition Co. I raised shares of NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.